DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
Z160
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia, Postherpetic; Radiculopathy
Voltage-gated N-type calcium channel alpha-1B subunit blocker
Z160
×
Maximum Phase:
2
First Approval:
None
UNII:
TX3R141LEP
Molecule Type:
Small molecule
Molecular Formula:
C32H32N2O
Molecular Weight:
460.62
AlogP:
6.14
PSA:
23.55
HBD:
0.0
HBA:
#RotB:
7.0
Source:
BINDARIT
2
Small molecule
Investigational
Unknown
Unknown
Coronary Restenosis; Diabetic Nephropathies
Unknown
BINDARIT
×
Maximum Phase:
2
First Approval:
None
UNII:
JQ11LH711M
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O3
Molecular Weight:
324.38
AlogP:
3.46
PSA:
64.35
HBD:
1.0
HBA:
#RotB:
6.0
Source:
AURICLOSENE
2
Small molecule
Investigational
Unknown
Unknown
Conjunctivitis, Bacterial; Conjunctivitis, Viral; Impetigo
Unknown
AURICLOSENE
×
Maximum Phase:
2
First Approval:
None
UNII:
BKR7Y95229
Molecule Type:
Small molecule
Molecular Formula:
C4H9Cl2NO3S
Molecular Weight:
222.09
AlogP:
1.26
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
3.0
Source:
SURINABANT
2
Small molecule
Investigational
Unknown
Unknown
Obesity; Smoking Cessation
Cannabinoid CB1 receptor antagonist
SURINABANT
×
Maximum Phase:
2
First Approval:
None
UNII:
SF8R9VCB0X
Molecule Type:
Small molecule
Molecular Formula:
C23H23BrCl2N4O
Molecular Weight:
522.27
AlogP:
6.3
PSA:
50.16
HBD:
1.0
HBA:
#RotB:
5.0
Source:
PATIDEGIB HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PATIDEGIB HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
ZL14FCA5PK
Molecule Type:
Small molecule
Molecular Formula:
C29H49ClN2O3S
Molecular Weight:
541.24
AlogP:
5.03
PSA:
67.43
HBD:
2.0
HBA:
#RotB:
2.0
Source:
LUNACALCIPOL
2
Small molecule
Investigational
Unknown
Unknown
Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Psoriasis; Renal Insufficiency, Chronic
Vitamin D receptor agonist
LUNACALCIPOL
×
Maximum Phase:
2
First Approval:
None
UNII:
XN4TL6M50Z
Molecule Type:
Small molecule
Molecular Formula:
C28H42O4S
Molecular Weight:
474.71
AlogP:
5.8
PSA:
74.6
HBD:
2.0
HBA:
#RotB:
5.0
Source:
QBW251
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive
Cystic fibrosis transmembrane conductance regulator activator
QBW251
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DABUZALGRON
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Alpha-1a adrenergic receptor partial agonist
DABUZALGRON
×
Maximum Phase:
2
First Approval:
None
UNII:
LGX4GZ74WO
Molecule Type:
Small molecule
Molecular Formula:
C12H16ClN3O3S
Molecular Weight:
317.8
AlogP:
1.4
PSA:
79.79
HBD:
2.0
HBA:
#RotB:
5.0
Source:
BISEGLIPTIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibitor
BISEGLIPTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
9U5KQ79OK6
Molecule Type:
Small molecule
Molecular Formula:
C18H26FN3O3
Molecular Weight:
351.42
AlogP:
1.69
PSA:
82.43
HBD:
1.0
HBA:
#RotB:
5.0
Source:
CORTODOXONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CORTODOXONE
×
Maximum Phase:
2
First Approval:
None
UNII:
WDT5SLP0HQ
Molecule Type:
Small molecule
Molecular Formula:
C21H30O4
Molecular Weight:
346.47
AlogP:
2.81
PSA:
74.6
HBD:
2.0
HBA:
#RotB:
2.0
Source:
VERUBULIN
2
Small molecule
Investigational
Unknown
Unknown
Brain Neoplasms; Neoplasms; Glioblastoma
Tubulin disrupting agent
VERUBULIN
×
Maximum Phase:
2
First Approval:
None
UNII:
X97O9FTB92
Molecule Type:
Small molecule
Molecular Formula:
C17H17N3O
Molecular Weight:
279.34
AlogP:
3.71
PSA:
38.25
HBD:
0.0
HBA:
#RotB:
3.0
Source:
TRELANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 1b (5-HT1b) receptor antagonist
TRELANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
QUD44MBL5S
Molecule Type:
Small molecule
Molecular Formula:
C24H24FN5O2S
Molecular Weight:
465.55
AlogP:
2.6
PSA:
84.46
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PIPENDOXIFENE
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
PIPENDOXIFENE
×
Maximum Phase:
2
First Approval:
None
UNII:
TPC5Q8496G
Molecule Type:
Small molecule
Molecular Formula:
C29H32N2O3
Molecular Weight:
456.59
AlogP:
5.94
PSA:
57.86
HBD:
2.0
HBA:
#RotB:
7.0
Source:
GSK-1521498
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Obesity
Mu opioid receptor antagonist
GSK-1521498
×
Maximum Phase:
2
First Approval:
None
UNII:
W0UTB622GK
Molecule Type:
Small molecule
Molecular Formula:
C24H20F2N4
Molecular Weight:
402.45
AlogP:
4.67
PSA:
53.6
HBD:
2.0
HBA:
#RotB:
5.0
Source:
L-EFLORNITHINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
L-EFLORNITHINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
UO07O10TCJ
Molecule Type:
Small molecule
Molecular Formula:
C6H13ClF2N2O2
Molecular Weight:
218.63
AlogP:
-0.23
PSA:
89.34
HBD:
3.0
HBA:
#RotB:
5.0
Source:
GS-0976
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GS-0976
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IBERDOMIDE
2
Small molecule
Investigational
Unknown
Unknown
Renal Insufficiency; Multiple Myeloma
CRL4(CRBN) E3 ubiquitin ligase modulator
IBERDOMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
8V66F27X44
Molecule Type:
Small molecule
Molecular Formula:
C25H27N3O5
Molecular Weight:
449.51
AlogP:
1.86
PSA:
88.18
HBD:
1.0
HBA:
#RotB:
6.0
Source:
HPPH
2
Small molecule
Investigational
Unknown
Unknown
Adenocarcinoma of Lung; Barrett Esophagus; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Esophageal Neoplasms; Lung Neoplasms; Oropharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck
Unknown
HPPH
×
Maximum Phase:
2
First Approval:
None
UNII:
DOB7Y3RSX0
Molecule Type:
Small molecule
Molecular Formula:
C39H48N4O4
Molecular Weight:
636.84
AlogP:
9.42
PSA:
120.96
HBD:
3.0
HBA:
#RotB:
11.0
Source:
MK-0457
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MK-0457
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EZATIOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes
Unknown
EZATIOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
057D10I8S8
Molecule Type:
Small molecule
Molecular Formula:
C27H35N3O6S
Molecular Weight:
529.66
AlogP:
2.5
PSA:
136.82
HBD:
3.0
HBA:
#RotB:
15.0
Source:
DAGLUTRIL
2
Small molecule
Investigational
Unknown
Unknown
Hypertension
Endothelin-converting enzyme 1 inhibitor
DAGLUTRIL
×
Maximum Phase:
2
First Approval:
None
UNII:
KKV299446X
Molecule Type:
Small molecule
Molecular Formula:
C31H38N2O6
Molecular Weight:
534.65
AlogP:
4.3
PSA:
113.01
HBD:
2.0
HBA:
#RotB:
11.0
Source:
HYDRONIDONE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Hepatitis B, Chronic
Unknown
HYDRONIDONE
×
Maximum Phase:
2
First Approval:
None
UNII:
RXQ128313W
Molecule Type:
Small molecule
Molecular Formula:
C12H11NO2
Molecular Weight:
201.22
AlogP:
1.85
PSA:
42.23
HBD:
1.0
HBA:
#RotB:
1.0
Source:
GAMMA-TOCOPHEROL
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Inflammation
Unknown
GAMMA-TOCOPHEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
8EF1Z1238F
Molecule Type:
Small molecule
Molecular Formula:
C28H48O2
Molecular Weight:
416.69
AlogP:
8.53
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
12.0
Source:
SB-773812
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Dopamine D2 receptor antagonist
SB-773812
×
Maximum Phase:
2
First Approval:
None
UNII:
ZNP5SNF9FY
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPELSIBAN
2
Small molecule
Investigational
Unknown
Unknown
Adenomyosis
Oxytocin receptor antagonist
EPELSIBAN
×
Maximum Phase:
2
First Approval:
None
UNII:
T2EZ19HX73
Molecule Type:
Small molecule
Molecular Formula:
C30H38N4O4
Molecular Weight:
518.66
AlogP:
2.76
PSA:
91.84
HBD:
1.0
HBA:
#RotB:
6.0
Source:
AZD-5423
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
Glucocorticoid receptor modulator
AZD-5423
×
Maximum Phase:
2
First Approval:
None
UNII:
641H0Q518W
Molecule Type:
Small molecule
Molecular Formula:
C25H21F4N3O3
Molecular Weight:
487.45
AlogP:
5.36
PSA:
65.38
HBD:
1.0
HBA:
#RotB:
7.0
Source:
ZAMICASTAT
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary
Dopamine beta-hydroxylase inhibitor
ZAMICASTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
YLU32D0DNV
Molecule Type:
Small molecule
Molecular Formula:
C21H21F2N3OS
Molecular Weight:
401.48
AlogP:
4.33
PSA:
41.98
HBD:
2.0
HBA:
#RotB:
6.0
Source:
SERABELISIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms
PI3-kinase p110-alpha subunit inhibitor
SERABELISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
43J9Q56T3W
Molecule Type:
Small molecule
Molecular Formula:
C19H17N5O3
Molecular Weight:
363.38
AlogP:
2.2
PSA:
98.89
HBD:
1.0
HBA:
#RotB:
2.0
Source:
KRP203
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Colitis, Ulcerative; Lupus Erythematosus, Cutaneous
Sphingosine 1-phosphate receptor Edg-1 agonist
KRP203
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
POTASSIUM HYDROXIDE
2
Small molecule
Investigational
Unknown
Unknown
Molluscum Contagiosum
Unknown
POTASSIUM HYDROXIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
WZH3C48M4T
Molecule Type:
Small molecule
Molecular Formula:
HKO
Molecular Weight:
56.1
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
RAZUPENEM
2
Small molecule
Investigational
Unknown
Unknown
Infections
Bacterial penicillin-binding protein inhibitor
RAZUPENEM
×
Maximum Phase:
2
First Approval:
None
UNII:
26020H3Q1L
Molecule Type:
Small molecule
Molecular Formula:
C18H21N3O4S2
Molecular Weight:
407.52
AlogP:
1.76
PSA:
102.76
HBD:
3.0
HBA:
#RotB:
5.0
Source:
AZOXIMER BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
AZOXIMER BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
90G53638ZD
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMONIDAZOLE
2
Small molecule
Investigational
Unknown
Unknown
Rectal Neoplasms; Aortic Aneurysm, Thoracic; Prostatic Neoplasms, Castration-Resistant; Tuberculosis, Pulmonary
Unknown
PIMONIDAZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
46JO4D76R2
Molecule Type:
Small molecule
Molecular Formula:
C11H18N4O3
Molecular Weight:
254.29
AlogP:
0.64
PSA:
84.43
HBD:
1.0
HBA:
#RotB:
5.0
Source:
ACLIMOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Methionine aminopeptidase 2 inhibitor
ACLIMOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
X150A3JK8R
Molecule Type:
Small molecule
Molecular Formula:
C26H42N2O6
Molecular Weight:
478.63
AlogP:
2.85
PSA:
76.3
HBD:
0.0
HBA:
#RotB:
8.0
Source:
RAFABEGRON
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Beta-3 adrenergic receptor agonist
RAFABEGRON
×
Maximum Phase:
2
First Approval:
None
UNII:
LN3E1Q0SU2
Molecule Type:
Small molecule
Molecular Formula:
C21H23ClN2O4
Molecular Weight:
402.88
AlogP:
3.54
PSA:
94.58
HBD:
4.0
HBA:
#RotB:
9.0
Source:
1
2
…
117
118
119
120
121
122
123
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA